Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: Experiences and subgroup analysis in a cohort with frequent methotrexate use

Clinical and Experimental Rheumatology

Volumn 34, Issue 4, 2016, Pages 714-718

  Kostik, Mikhail M ^a   Gaidar, Ekaterina V ^a   Hynnes, Alla Y ^b   Dubko, Margarita F ^a   Masalova, Vera V ^a   Snegireva, Ludmila S ^a   Chikova, Irina A ^a   Isupova, Eugenia A ^a   Nikitina, Tatiana N ^a   Serogodskaya, Elena D ^a   Kalashnikova, Olga V ^a   Ravelli, Angelo ^c,d   Chasnyk, Vyacheslav G ^a  

^a SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^b Eye Care Physicians and Surgeons   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

Author keywords

Juvenile idiopathic arthritis; Methotrexate; Uveitis

Indexed keywords

ANTINUCLEAR ANTIBODY; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; ANTIRHEUMATIC AGENT;

ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RUSSIAN (PEOPLE); SEX DIFFERENCE; SURVIVAL ANALYSIS; UVEITIS; AGE; ARTHRITIS, JUVENILE; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; RUSSIAN FEDERATION; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RUSSIA; TIME FACTORS; TREATMENT OUTCOME; UVEITIS;

EID: 84984820691     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. SAURENMANN RK, LEVIN AV, FELDMAN BM et al.: Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow-up study. Arthritis Rheum 2007; 56: 647-57.
2. ROSENBERG KD, FEUER WJ, DAVIS JL: Ocular complications of paediatric uveitis. Ophthalmology 2004; 111: 2299-306.
3. De BOER J, WULFFRAAT N, ROTHOVA A: Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879-84.
4. CALANDRA S, GALLO MC, CONSOLARO A et al.: Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. J Rheumatol 2014; 41: 1416-25.
5. VERAZZA S, ALLEGRA M, LATTANZI B et al.: Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA). Pediatr Rheumatol Online J 2008; 6 (Suppl. 1): 77.
6. TAPPEINER C, KLOTSCHE J, SCHENCK S, NIEWERTH M, MINDEN K, HEILIGENHAUS A: Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis: data from a cross-sectional analysis of a prospective nationwide study. Clin Exp Rheumatol 2015; 33: 936-44.
7. ZANNIN ME, BUSCAIN I, VITTADELLO F et al.: Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. Acta Ophthalmol 2012; 90: 91-5.
8. ANGELES-HAN ST, PELAJO CF, VOGLER LB et al.: CARRA Registry Investigators. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 2013; 40: 2088-96.
9. GIANNINI EH, BREWER EJ, KUZMINA N et al.: Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992; 326: 1043-9.
10. RUPERTO N, MURRAY KJ, GERLONI V et al.: Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-201.
11. SIMONINI G, PAUDYAL P, JONES GT, CIMAZ R, MACFARLANE GJ: Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford) 2013; 52: 825-31
12. AYUSO VK, van de WINKEL EL, ROTHOVA A, de BOER JH: Relapse rate of uveitis postmethotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151: 217-22.
13. PAPADOPOULOU C, KOSTIK M, BOHM M et al.: Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr 2013; 163: 879-84.
14. BEUKELMAN T, PATKAR NM, SAAG KG et al.: 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 63: 465-82.
15. PETTY RE, SOUTHWOOD TR, MANNERS P et al.: International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
16. BLOCH-MICHEL E, NUSSENBLATT RB: International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987; 103: 234-5.
17. JABS DA, NUSSENBLATT RB, ROSENBAUM JT; Standardization of Uveitis Nomenclature (SUN) Working Group: Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-16.
18. PUCHTA J, HATTENBACH LO, BAATZ H: Intraocular levels of methotrexate after oral low-dose treatment in chronic uveitis. Ophthalmologica 2005; 219: 54-5.
19. de SMET MD, STARK-VANCS V, KOHLER DR, SMITH J, WITTES R, NUSSENBLATT RB: Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 1996; 121: 442-4
20. FOELDVARI I, THME N, HORNEFF G: Methotrexate is protective against the new onset of uveitis under etanercept treatment. Data from the German Etanercept Registry. Ann Rheum Dis 2010; 69 (Suppl. 3): 626.